I mentioned in previous articles that genotypes of Chinese hepatitis C patients are mainly 1b and 2a/c, with the number of hepatitis C patients of about 26 million in total but treatment rate of less than 0.5%! The market space is huge.
Since the marketing of DAAs in 2017, many DAAs have entered China, which will change the traditional hepatitis C therapeutic regimen of peginterferon (Peg-IFN-α) in combination with ribavirin. China has begun to enter the era of hepatitis C cure!!
So far, there have been many enterprises marketing DAA hepatitis C drugs in China, and Kawin Technology, Gilead, and AbbVie separately have one relevant drug filed the marketing application to NMPA.